PMID- 24579885
OWN - NLM
STAT- MEDLINE
DCOM- 20140618
LR  - 20240509
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 165
IP  - 4
DP  - 2014 May
TI  - SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for 
      relapsed/refractory acute lymphocytic leukaemia.
PG  - 504-9
LID - 10.1111/bjh.12778 [doi]
AB  - Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of 
      ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell 
      surface. In the present study (Southwestern Oncology Group S0910), we evaluated 
      the addition of epratuzumab, a humanized monoclonal antibody against CD22, to the 
      combination of clofarabine and cytarabine in adults with relapsed/refractory 
      pre-B ALL. The response rate [complete remission and complete remission with 
      incomplete count recovery] was 52%, significantly higher than our previous trial 
      with clofarabine/cytarabine alone, where the response rate was 17%. This result 
      is encouraging and suggests a potential benefit to adding epratuzumab to 
      chemotherapy for ALL; however, a randomized trial will be needed to answer this 
      question.
CI  - (c) 2014 John Wiley & Sons Ltd.
FAU - Advani, Anjali S
AU  - Advani AS
AD  - Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, The Cleveland 
      Clinic, Cleveland, OH, USA.
FAU - McDonough, Shannon
AU  - McDonough S
FAU - Coutre, Steven
AU  - Coutre S
FAU - Wood, Brent
AU  - Wood B
FAU - Radich, Jerald
AU  - Radich J
FAU - Mims, Martha
AU  - Mims M
FAU - O'Donnell, Margaret
AU  - O'Donnell M
FAU - Elkins, Stephanie
AU  - Elkins S
FAU - Becker, Michael
AU  - Becker M
FAU - Othus, Megan
AU  - Othus M
FAU - Appelbaum, Frederick R
AU  - Appelbaum FR
LA  - eng
GR  - N01 CA004919/CA/NCI NIH HHS/United States
GR  - CA073590/CA/NCI NIH HHS/United States
GR  - N01 CA032102/CA/NCI NIH HHS/United States
GR  - CA38936/CA/NCI NIH HHS/United States
GR  - CA11083/CA/NCI NIH HHS/United States
GR  - CA16385/CA/NCI NIH HHS/United States
GR  - U10 CA032102/CA/NCI NIH HHS/United States
GR  - U10 CA073590/CA/NCI NIH HHS/United States
GR  - U10 CA038926/CA/NCI NIH HHS/United States
GR  - U10 CA042777/CA/NCI NIH HHS/United States
GR  - U10 CA046368/CA/NCI NIH HHS/United States
GR  - U10 CA180819/CA/NCI NIH HHS/United States
GR  - U10 CA058861/CA/NCI NIH HHS/United States
GR  - U10 CA016385/CA/NCI NIH HHS/United States
GR  - U10 CA004919/CA/NCI NIH HHS/United States
GR  - CA58861/CA/NCI NIH HHS/United States
GR  - CA46282/CA/NCI NIH HHS/United States
GR  - U10 CA046282/CA/NCI NIH HHS/United States
GR  - CA46368/CA/NCI NIH HHS/United States
GR  - CA67663/CA/NCI NIH HHS/United States
GR  - CA42777/CA/NCI NIH HHS/United States
GR  - U10 CA011083/CA/NCI NIH HHS/United States
GR  - U10 CA067663/CA/NCI NIH HHS/United States
GR  - U10 CA180888/CA/NCI NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20140303
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Adenine Nucleotides)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Arabinonucleosides)
RN  - 0 (CD22 protein, human)
RN  - 0 (Sialic Acid Binding Ig-like Lectin 2)
RN  - 04079A1RDZ (Cytarabine)
RN  - 3062P60MH9 (epratuzumab)
RN  - 762RDY0Y2H (Clofarabine)
SB  - IM
MH  - Adenine Nucleotides/administration & dosage/adverse effects
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/administration & dosage/adverse 
      effects/immunology
MH  - Antigens, Neoplasm/immunology
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Arabinonucleosides/administration & dosage/adverse effects
MH  - Chemical and Drug Induced Liver Injury/etiology
MH  - Clofarabine
MH  - Cytarabine/administration & dosage/adverse effects
MH  - Febrile Neutropenia/chemically induced
MH  - Female
MH  - Heart Arrest/chemically induced
MH  - Hematologic Diseases/chemically induced
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/genetics
MH  - Recurrence
MH  - Remission Induction
MH  - Risk
MH  - *Salvage Therapy
MH  - Sialic Acid Binding Ig-like Lectin 2/immunology
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC4209396
MID - NIHMS563955
OTO - NOTNLM
OT  - CD22
OT  - Treatment
OT  - acute lymphocytic leukaemia
OT  - epratuzumab
OT  - relapse
COIS- Conflict of Interest: AS Advani has received some funding and honoraria from 
      Genzyme
EDAT- 2014/03/04 06:00
MHDA- 2014/06/19 06:00
PMCR- 2015/05/01
CRDT- 2014/03/04 06:00
PHST- 2013/10/26 00:00 [received]
PHST- 2013/12/27 00:00 [accepted]
PHST- 2014/03/04 06:00 [entrez]
PHST- 2014/03/04 06:00 [pubmed]
PHST- 2014/06/19 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - 10.1111/bjh.12778 [doi]
PST - ppublish
SO  - Br J Haematol. 2014 May;165(4):504-9. doi: 10.1111/bjh.12778. Epub 2014 Mar 3.